A Phase 4 interventional study of Osilodrostat and Placebo in Hypertension, Hypercortisolemia and Cushing Syndrome, sponsored by RECORDATI GROUP. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by RECORDATI GROUP · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 1,052nd largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2026, is one of 188 in phase 4, reaches primary completion later than 256 of the 367 other live ones, and was the 1,941st registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 101 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
RECORDATI GROUP has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 mg QOD
Drug: Osilodrostat
matching placebo
Drug: Placebo
Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.
Also known as: isturisa
matching placebo
To evaluate the efficacy of osilodrostat on the proportion of participants with normalization of urinary-free cortisol (UFC)
Normalization status for each participant at Week 30 of treatment with osilodrostat or placebo, based on the mean of UFC concentrations from two 24-hour urine collections, with normalization defined as ≤1× the upper limit of normal (ULN).
Time frame: 30 weeks
Percentage of Participants With Blood Pressure Response by 24-Hour Ambulatory Blood Pressure Monitoring (ABPM) at Week 30 (key secondary)
Blood pressure (BP) responder status is assessed by 24-hour ABPM. This measure will check the % of participants that are responders. A participant is a responder if mean systolic and/or diastolic BP decreases by at least 5 mmHg from baseline, without worsening of either and without any modification in antihypertensive medication attributable to worsening hypertension. Participants without a valid ABPM assessment at Week 30 are classified as non-responders.
Time frame: Week 30
Percentage of Participants With Hypocortisolism-Related Adverse Events (Overall)
Percentage of participants with at least one hypocortisolism-related adverse event (AE) during the treatment period.
Time frame: Week 30
Percentage of Participants With Glucocorticoid Withdrawal Syndrome
Percentage of participants with glucocorticoid withdrawal syndrome, a category of hypocortisolism-related AEs, during the treatment period.
Time frame: Week 30
Percentage of Participants With Confirmed Adrenal Insufficiency
Percentage of participants with confirmed adrenal insufficiency, a category of hypocortisolism-related AEs, during the treatment period.
Time frame: Week 30
Percentage of Participants With Glycemic Response at Week 30 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). A glycemic responder has a reduction of at least 25% from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT), without the addition of, or an increase in the dose of, glucose-lowering medications.
Time frame: baseline and Week 30
Percentage of Participants With Glycemic Response at Week 21 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). A glycemic responder has a reduction of at least 25% from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT), without the addition of, or an increase in the dose of, glucose-lowering medications.
Time frame: Baseline and Week 21
Percentage of Participants With Body Weight Response at Week 30
A body weight responder has a decrease of at least 5% from baseline in body weight, without the addition of, or an increase in the dose of, weight-lowering medications.
Time frame: baseline and Week 30
Percentage of Participants With Body Weight Response at Week 21
A body weight responder has a decrease of at least 5% from baseline in body weight, without the addition of, or an increase in the dose of, weight-lowering medications.
Time frame: baseline and Week 21
Change From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 30
Change from baseline in mean 24-hour SBP measured by ambulatory blood pressure monitoring (ABPM). Change = value at Week 30 minus baseline value.
Time frame: Baseline, Week 30
Change From Baseline in Systolic Blood Pressure (SBP) by 24-Hour ABPM at Week 21
Change from baseline in mean 24-hour SBP measured by ambulatory blood pressure monitoring (ABPM). Change = value at Week 21 minus baseline value.
Time frame: baseline and Week 21
Change From Baseline in Glucose AUC During OGTT at Week 30 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT). Change = value at Week 30 minus baseline value.
Time frame: baseline and Week 30
Change From Baseline in Glucose AUC During OGTT at Week 21 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT). Change = value at Week 21 minus baseline value.
Time frame: baseline and Week 21
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 30 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = HbA1c value at Week 30 minus baseline value.
Time frame: baseline and Week 30
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 21 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = HbA1c value at Week 21 minus baseline value.
Time frame: baseline and Week 21
Change From Baseline in 2-Hour Postprandial Glucose at Week 30 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = 2-hour postprandial glucose value at Week 30 minus baseline value.
Time frame: Baseline, Week 30
Change From Baseline in 2-Hour Postprandial Glucose at Week 21 in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change = 2-hour postprandial glucose value at Week 21 minus baseline value.
Time frame: baseline and Week 21
Change From Baseline in Fasting Plasma Glucose Over Time in Participants With High-Risk Dysglycemia
Assessed in participants with high-risk dysglycemia at baseline (HbA1c \>=6.0%). Change from baseline in fasting plasma glucose (FPG) at each scheduled visit.
Time frame: Up to Week 30
Change From Baseline in Body Weight Over Time
Change from baseline in body weight at each scheduled visit.
Time frame: Up to Week 30
Participants (n) With Adverse Events
Frequency of participants with AEs, by treatment group, during the treatment period.
Time frame: Up to Week 30
Participants (%) With Adverse Events
percentage of participants with AEs, by treatment group, during the treatment period.
Time frame: Up to Week 30
Change From Baseline in Laboratory Values
Change from baseline in safety laboratory values at each scheduled visit.
Time frame: Up to Week 30
Change From Baseline in Electrocardiogram (ECG) Parameters
Change from baseline in ECG readings at each scheduled visit.
Time frame: Up to Week 30
Change From Baseline in Vital Signs
Change from baseline in vital signs at each scheduled visit.
Time frame: Up to Week 30
Shift in American Heart Association (AHA) Hypertension Category From Baseline to Week 30
Distribution of participants by AHA blood pressure classification category at Week 30 compared with baseline.
Time frame: baseline and Week 30
Shift in American Heart Association (AHA) Hypertension Category From Baseline to Week 21
Distribution of participants by AHA blood pressure classification category at Week 21 compared with baseline.
Time frame: baseline and Week 21
Shift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 30
Distribution of participants by ADA glycemia classification category at Week 30 compared with baseline.
Time frame: baseline and Week 30
Shift in American Diabetes Association (ADA) Glycemia Category From Baseline to Week 21
Distribution of participants by ADA glycemia classification category at Week 21 compared with baseline.
Time frame: baseline and Week 21
Change From Baseline in Blood Pressure-Lowering Medications (Dose Changes) at Week 30
Distribution of dose changes (increase, decrease, no change) of blood pressure-lowering medications at Week 30 compared with baseline.
Time frame: baseline and Week 30
Change From Baseline in Blood Pressure-Lowering Medications (Number) at Week 30
number of blood pressure-lowering medications at Week 30 compared with baseline.
Time frame: baseline and Week 30
Change From Baseline in Blood Pressure-Lowering Medications (Number) at Week 21
number of blood pressure-lowering medications at Week 21 compared with baseline.
Time frame: baseline and Week 21
Change From Baseline in Blood Pressure-Lowering Medications (Dose Change) at Week 21
Distribution of dose changes (increase, decrease, no change) of blood pressure-lowering medications at Week 21 compared with baseline.
Time frame: baseline and Week 21
Change From Baseline in Glucose-Lowering Medications (Dose Changes) at Week 30
Distribution of dose changes (increase, decrease, no change) of glucose-lowering medications at Week 30 compared with baseline.
Time frame: baseline and Week 30
Change From Baseline in Glucose-Lowering Medications (Dose Changes) at Week 21
Distribution of dose changes (increase, decrease, no change) of glucose-lowering medications at Week 21 compared with baseline.
Time frame: Baseline, Week 21
Change From Baseline in Glucose-Lowering Medications (Number) at Week 30
number of glucose-lowering medications at Week 30 compared with baseline.
Time frame: Baseline, Week 30
Change From Baseline in Glucose-Lowering Medications (Number) at Week 21
number of glucose-lowering medications at Week 21 compared with baseline.
Time frame: baseline and Week 21
Percentage of Participants With Normalization of 24-Hour Urinary Free Cortisol (UFC) Over Time
Normalization status of 24-hour UFC for each participant at each scheduled visit, defined as UFC \<=1x the upper limit of normal (ULN).
Time frame: up Week 30
Percentage of Participants With Blood Pressure Response by 24-Hour ABPM at Week 21
Blood pressure (BP) responder status is assessed by 24-hour ABPM. A participant is a responder if mean systolic and/or diastolic BP decreases by at least 5 mmHg from baseline, without worsening of either and without any modification in antihypertensive medication attributable to worsening hypertension.
Time frame: Week 21
Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.
Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 21 months is close to that.
Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat